Tumescent antibiotic solution
View Patent ↗Disclosed herein are solutions and kits for tumescent antibiotic delivery. Embodiments of the solution comprise an antibiotic component, an anesthetic component and a vasoconstrictor component. In addition, a method of use is disclosed comprising subcutaneous delivery of the solution. The disclosed solution, kit and method of subcutaneous delivery can be used for a variety of surgical procedures including liposuction, mastectomy and others. The tumescent antibiotic solution can be administered to a patient in situations where establishing IV access is difficult, impossible, or undesirable. A variety of delivery methods appropriate for surgical settings, as well as for use by first responders are likewise disclosed.
1. A method of reducing the risk of thromboembolism in a patient during a medical procedure, comprising administering into the subcutaneous fat compartment of the patient a composition comprising an antibiotic component, a vasoconstrictor component and an anesthetic component, in a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein the anesthetic component comprises lidocaine.
3. The method of claim 2 , wherein the concentration of lidocaine is approximately 400 mg to 1,200 mg per liter of solution.
4. The method of claim 1 , wherein the vasoconstrictor component comprises epinephrine.
5. The method of claim 4 , wherein the concentration of epinephrine is approximately 0.4 to 1.2 mg per liter.
6. The method of claim 1 , wherein the antibiotic component comprises cefazolin.
7. The method of claim 1 , wherein the antibiotic component comprises a mixture of two or more antibiotics.
8. The method of claim 1 , wherein the composition further comprises an anti-inflammatory agent.
9. The method of claim 1 , wherein the medical procedure is liposuction.
10. The method of claim 1 , wherein the medical procedure comprises removal of subcutaneous tissue from the patient.
11. The method of claim 1 , wherein the medical procedure is a mastectomy.
12. The method of claim 6 , wherein the cefazolin is at a concentration of between 250 to 1000 mg per liter of solvent.
13. The method of claim 1 , wherein the composition has an acidic pH.
14. The method of claim 1 , wherein the vasoconstrictor component comprises a mixture of epinephrine and one or more vasoconstrictors other than epinephrine.